The outlook of companies tied to the drug's legacy presents a intricate investment landscape. While the initial boom generated substantial returns , generic alternatives have significantly diminished market https://sb-bookmarking.com/story21741342/copyright-s-flagship-product-and-the-pharmaceutical-sector-a-risky-opportunity